At a Glance
- Company: SonoThera
- Funding: $125 million Series B
- Focus area: Non-viral gene therapy
- Next steps: Advance platform development and pipeline work
What happened?
SonoThera has raised $125 million in Series B financing to support development of its non-viral gene therapy platform. The new capital will help the company push its technology further as it works on next-generation genetic medicines.
Why does it matter?
Non-viral delivery is one of the key bottlenecks in gene therapy, because it could make treatments safer, more flexible and easier to scale than viral vector approaches. If SonoThera’s platform works as intended, it could broaden the range of diseases that gene therapy can address.
Who’s behind it?
SonoThera is a biotech company focused on developing delivery technologies for genetic medicines. Its work centres on enabling large or complex genetic cargo to reach target cells without relying on viral vectors.
How was it achieved?
The company’s platform uses non-viral delivery methods rather than engineered viruses to transport therapeutic genetic material. That approach is intended to improve payload capacity and potentially reduce some of the manufacturing and safety challenges associated with viral systems.
What’s next?
SonoThera is expected to use the funding to advance its platform, refine its delivery technology and move programmes closer to the clinic. The Series B should also support further research and development across its gene therapy pipeline.